Bromantane · Research brief
Bromantane In Vitro Study and Animal Model Findings
Short answer
A bromantane in vitro study is a laboratory experiment in which the adamantane derivative bromantane is applied to cultured cells, isolated tissue or a cell-free biochemical system and a molecular endpoint such as gene expression, enzyme activity or transporter function is measured, while a bromantane animal study places the same compound into whole rodents and reads out neurochemistry, behaviour, physical…
A bromantane in vitro study is a laboratory experiment in which the adamantane derivative bromantane is applied to cultured cells, isolated tissue or a cell-free biochemical system and a molecular endpoint such as gene expression, enzyme activity or transporter function is measured, while a bromantane animal study places the same compound into whole rodents and reads out neurochemistry, behaviour, physical work capacity or immune parameters. The honest summary of the field is that animal work dominates and true cell-based work is sparse: most of the primary record was generated in Soviet and Russian experimental pharmacology laboratories between the late 1980s and the mid 2000s, much of it published in Russian-language journals with brief indexed abstracts, and a large share of what is casually described online as in vitro data is in fact ex vivo tissue analysis taken from treated animals. This page sets out what the models were, what endpoints they measured, what the accessible English-language synthesis reports, and where the gaps sit.
What is bromantane, and why does a preclinical literature exist for it?
Bromantane is a synthetic small molecule built from an adamantane cage linked through a secondary amine to a para-bromophenyl ring, with the molecular formula C16H20BrN and a molar mass near 306 g/mol; it is commonly listed under CAS 87913-26-6, a figure that should always be checked against the certificate of analysis for a given lot rather than assumed. It is not a peptide, and it sits structurally alongside other adamantane derivatives rather than alongside the stimulant amines it is often compared to.
The reason a preclinical literature exists at all is that bromantane was developed inside a Soviet research program interested in compounds that could sustain performance under unfavourable physical conditions such as heat, low oxygen and prolonged exertion. The English-language review of this class, The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance (PMID 24009833), published in Biomolecules and Therapeutics in 2012, describes actoprotectors as agents studied for maintaining working capacity under stress without the metabolic cost and rebound exhaustion attributed to classical psychostimulants, and it places bromantane within that research category alongside other Soviet-era compounds.
Bromantane later became visible outside pharmacology through anti-doping analysis, after the compound was identified in competition samples during the 1990s, and it is listed by the World Anti-Doping Agency among prohibited stimulant substances. That history matters for a research brief for two reasons. First, it means a parallel analytical literature exists on detection and metabolite identification that is separate from the pharmacology literature. Second, it means the compound attracts a volume of secondary commentary far larger than the primary evidence supports, which is exactly the situation in which a structured index of models and endpoints is more useful than another narrative summary.
What does a bromantane in vitro study actually measure?
An in vitro study measures what the compound does to a biological system that has been removed from the animal, and for bromantane the endpoints that appear in the literature cluster into four groups. The first is gene and protein expression, specifically the enzymes of the catecholamine synthesis pathway such as tyrosine hydroxylase and aromatic L-amino acid decarboxylase, read out by transcript quantification and by protein detection. The second is transporter and receptor interaction, meaning binding or uptake assays at the dopamine, serotonin and noradrenaline transporters and radioligand panels across receptor families. The third is enzyme activity, including monoamine oxidase assays. The fourth is basic cell health, meaning viability and membrane integrity readouts that establish whether an observed signal is pharmacology or toxicity.
A critical distinction runs through the field. When sources state that bromantane increases the expression of dopamine synthesis enzymes, the underlying experiments were frequently performed on brain structures dissected from treated rodents, with the molecular measurement done at the bench afterwards. That is ex vivo work. It carries the whole-animal context, including metabolism and feedback from intact circuits, but it cannot establish that the compound acts directly on the cells in question, because a circulating metabolite or an upstream circuit could be responsible. A genuine cell-based experiment, in which a defined concentration contacts a defined cell type with no intact organism in between, answers a narrower and cleaner question, and the published supply of that kind of bromantane experiment is thin.
Physicochemistry also constrains what can be measured. The adamantane cage makes the molecule strongly lipophilic and poorly water soluble, so cell work depends on organic carrier solvents and on properly matched vehicle control arms; without them, apparent effects at higher concentrations are difficult to separate from solvent artefacts or from compound precipitation in the well. Any laboratory reading the older literature should check whether vehicle controls, solubility limits and cytotoxicity windows were reported, because in many mid-1990s reports those details are either absent from the abstract or absent from the paper.
What have cell and tissue level experiments reported about dopamine synthesis enzymes?
The central molecular claim in the bromantane literature is that the compound increases the capacity of dopaminergic neurons to make dopamine rather than forcing the release of what is already stored. Published reports summarised in the actoprotector review describe increased expression of tyrosine hydroxylase, the rate-limiting enzyme of catecholamine synthesis, and of aromatic L-amino acid decarboxylase, the enzyme that converts L-DOPA to dopamine, in hypothalamic and midbrain tissue from treated rodents. Research of this kind suggests a transcriptional or translational mechanism with a slower onset than transporter-mediated effects, which is the mechanistic argument behind describing bromantane as an indirect dopaminergic agent rather than a releaser.
The evidentiary limits here are substantial and should be stated plainly. The expression findings come largely from a small number of laboratories working in the same research tradition, over a period when reporting standards for randomisation, blinding, sample size justification and raw data availability were different from current expectations. The English-language indexed record does not contain a body of independent replications from unrelated groups. Transcript-level changes were not always accompanied by protein-level confirmation and functional enzyme activity in the same report, and a change in transcript abundance in dissected tissue does not by itself establish increased dopamine synthesis flux in a living circuit.
A modern verification of this mechanism would need an orthogonal design: transcript quantification, protein detection and enzyme activity in the same preparation, a concentration ladder with cytotoxicity bracketing, a time course that separates early from late changes, and a positive control compound with an established effect on the same pathway. Until that exists, the proposition that bromantane acts by upregulating catecholamine synthesis enzymes is best described as a mechanistic hypothesis with supportive but dated and geographically concentrated evidence, not as a settled finding.
What does bromantane animal study work report about brain monoamine levels?
Animal neurochemistry is the strongest part of the bromantane record in volume, if not in modern methodological quality. The standard approaches are tissue monoamine content, in which brain regions are dissected and dopamine, serotonin, noradrenaline and their metabolites are quantified by chromatography, and in vivo microdialysis in freely moving rats, in which extracellular neurotransmitter concentrations are sampled from the striatum or other targets over time. Reports collected in the actoprotector review describe increases in extracellular dopamine in striatal tissue after exposure in rodents, with a profile characterised as slower in onset and more sustained than that produced by amphetamine-type releasers, and with accompanying changes in metabolite ratios interpreted as reflecting altered synthesis and turnover rather than mass vesicular release.
The literature also reports serotonergic involvement, with measured changes in serotonin and its metabolite in some brain regions, although the serotonergic picture is less consistent across reports than the dopaminergic one. Interpretation is complicated by the fact that metabolite ratios are indirect indices: an increased ratio can arise from increased release, increased enzymatic breakdown or reduced reuptake, and distinguishing among these requires converging methods.
The limits of this work are the limits of 1990s microdialysis generally. Probe placement verification, strain and sex of the animals, anaesthesia history, baseline stabilisation time and sampling interval all shift the results, and these parameters are reported unevenly across the primary reports. Most of the work used male rats of a small number of strains, so generalisation across sex and genetic background is unsupported. Perhaps most importantly, the neurochemical findings have not been reproduced in the open English-language literature by groups outside the original research tradition, so the field has consistency within one lineage of work rather than independent convergence.
Which behavioural models appear most often in the rodent literature?
The behavioural battery used with bromantane is the standard rodent set of its era. Locomotor activity and exploration were assessed in open field arenas, anxiety-like behaviour in elevated plus maze and light and dark transition tests, behavioural despair in forced swim and tail suspension paradigms, learning and retention in avoidance and maze tasks, and stimulant character in tests for stereotypy and for interaction with reference stimulants. Reports summarised in the actoprotector review describe a profile of mild behavioural activation without the stereotyped behaviour typical of strong dopamine releasers, together with reduced anxiety-like behaviour in conflict and approach-avoidance tasks, a combination that the original authors framed as an unusual mix of activating and calming features.
Behavioural work of this period carries well-known interpretive hazards. Open field activity is sensitive to arena size, illumination, habituation history and handling, and an increase in distance travelled can reflect reduced anxiety, increased arousal or reduced freezing, which are not the same construct. Elevated plus maze results shift with time of day and with prior test exposure. Forced swim immobility is widely used but is a measure of coping behaviour rather than of mood, and it is confounded by any compound that changes motor output, which is exactly the concern with a reportedly activating agent. Where a compound alters locomotion, anxiety-like and despair-type readouts cannot be interpreted without a locomotor covariate, and the older bromantane reports do not consistently show that control.
The practical conclusion for a researcher indexing this literature is that the behavioural signal is reported consistently in direction but weakly specified in method. Group sizes, blinding of scorers, randomisation and statistical approach are rarely described in the detail a current journal would require, and automated tracking was not universal. The behaviour described is therefore a reasonable starting hypothesis for new work rather than a characterised behavioural pharmacology.
What do physical performance and stress tolerance models report?
The actoprotector framing rests on whole-animal performance models, and these are the experiments the class was named for. The usual designs are swimming to exhaustion with a weighted load, treadmill or running wheel endurance, survival or performance under reduced oxygen in a hypobaric or normobaric hypoxia chamber, and work capacity under elevated ambient temperature. The endpoint is typically time to exhaustion or a survival index, sometimes with accompanying tissue measurements such as lactate, glycogen or markers of oxidative stress.
The review of actoprotectors reports that compounds in this class, bromantane among them, were studied for preserved physical work capacity under heat and low oxygen conditions, with the stated contrast being that classical stimulants push performance at the cost of depleting reserves while actoprotectors were proposed to support performance with less subsequent decrement. Research of this kind suggests an effect on the organism's tolerance of adverse conditions rather than a simple motor stimulant effect, but the supporting data are performance curves in rodents, not mechanism.
The limits are considerable. Forced swim endurance is confounded by body mass and buoyancy, by thermoregulation in the water, and by motivational state, so two laboratories using nominally the same test can produce different results. Heat and hypoxia tolerance endpoints are highly sensitive to acclimatisation history and to chamber conditions. Few of the original reports provide the environmental detail that would allow replication, and the translation from a weighted swim in a rat to any conclusion about physical capacity in another species is not supported by the design. These are screening-level findings in whole animals, useful for prioritising mechanistic questions and not for claiming an outcome.
What does the preclinical record say about anxiety-like endpoints?
Anxiety-like behaviour is the endpoint where the bromantane literature diverges most sharply from what would be expected of a dopaminergic activator, and it is also where the mechanistic account is least resolved. Reports describe reduced anxiety-like behaviour in standard conflict and exploration tasks without the sedation or motor impairment that accompanies benzodiazepine-type reference compounds, and this profile is what led to the compound being studied in Russia under a separate name for stress-related indications. Proposed mechanisms in that literature include an interaction with GABAergic signalling in addition to the catecholamine synthesis effects, although the direct receptor-level evidence available in the indexed English-language record is limited.
An interesting methodological feature of this research tradition is the use of inbred mouse strains selected for differing emotional reactivity, with the premise that a compound's behavioural effect depends on the baseline stress phenotype of the animal. Studies built this way report that responses differ by strain, which is a useful caution for anyone attempting replication: a null result in one background does not refute a positive result in another, and a positive result in a high-anxiety strain does not generalise.
The limits again centre on reporting. Anxiety-like tests have low test-retest reliability and are strongly affected by housing, transport, lighting and experimenter identity. Without blinding and pre-specified analysis, the direction of an effect in a plus maze is a weak signal. The reasonable statement is that the published preclinical literature describes an anxiolytic-like behavioural profile in rodents, that the proposed GABAergic contribution remains a hypothesis rather than a demonstrated receptor-level mechanism, and that none of this supports any statement about effects in humans.
What has been reported on immune and inflammatory endpoints?
A smaller branch of the preclinical record examines immune parameters, reflecting a general interest in the Soviet adaptogen and actoprotector programs in compounds that might stabilise physiological systems disturbed by stress. The reported endpoints include counts and functional assays of immune cell populations, antibody responses to standard antigens, phagocytic activity and markers of inflammation, usually measured in animals exposed to a stressor such as restraint, cold or exhausting exercise.
The literature describes effects framed as normalising, meaning that parameters suppressed by a stressor were reported closer to control values in treated groups, rather than effects framed as generalised immune stimulation in healthy animals. That distinction is worth preserving when citing this work, because the two claims are often conflated in secondary sources. Research of this kind suggests a stress-buffering hypothesis, and nothing more.
The evidence here is the weakest part of the bromantane record. Immune endpoints in stressed rodents are notoriously variable, the assays used in the 1990s differ from current standards, cytokine panels were limited, and the available indexed abstracts rarely carry enough method detail to evaluate the work. There is no body of cell-based immunological work on bromantane in the open literature that would identify a receptor, pathway or cell type responsible. For an index of the evidence base, the immune findings belong in a clearly marked low-confidence tier, cited as historical observations that have not been independently verified rather than as established pharmacology.
What do animal models suggest about distribution, metabolism and detection?
The pharmacokinetic picture follows from the chemistry. A bulky adamantane cage with a halogenated aromatic ring produces a highly lipophilic molecule, and the literature describes rapid partitioning into lipid-rich tissue, including penetration of the blood-brain barrier, together with slow clearance from those compartments. The most practically documented consequence comes from analytical chemistry rather than pharmacology: anti-doping laboratories report long urinary detection windows for bromantane and its metabolites relative to many stimulants, which is consistent with tissue accumulation and slow redistribution.
Metabolite work in the analytical literature describes hydroxylation of the adamantane cage as a principal biotransformation route, producing more polar products that are detectable in urine, and detection methods are built around those products as well as the parent compound. For a laboratory planning bioanalytical work, this means that parent compound measurement alone may misrepresent exposure, and that reference standards for the hydroxylated species matter as much as the parent standard.
The gaps are significant. The indexed English-language record does not contain a detailed modern pharmacokinetic characterisation in rodents with reported clearance, volume of distribution, brain-to-plasma ratios and metabolite profiling in one coherent study. Species differences in adamantane hydroxylation are plausible but not mapped for this compound. Without that work, the relationship between an exposure level in an animal experiment and a concentration in a cell-based experiment cannot be reconciled, which is one reason the in vitro and in vivo branches of this literature remain difficult to integrate. Any statement connecting a concentration in a well to an effect in an animal should be treated as unsupported extrapolation.
How does the proposed mechanism differ from classical stimulants in preclinical models?
The mechanistic claim that defines bromantane in its source literature is that it increases dopaminergic tone through synthesis capacity rather than through forced release or transporter blockade. Amphetamine-type compounds reverse transporter function and empty vesicular stores, producing a rapid rise in extracellular dopamine, marked locomotor activation, stereotyped behaviour at higher exposures and a subsequent depletion phase. Cocaine-type compounds block reuptake, with a similarly fast onset. The preclinical reports on bromantane describe a slower rise, an absence of pronounced stereotypy and no clearly described depletion rebound, and they attach that profile to upregulated expression of the synthesis enzymes discussed above.
If accurate, this would be a mechanistically distinct profile, because a synthesis-driven effect is self-limiting in a way that a releaser is not: enzyme capacity constrains output, and feedback regulation of neuronal firing and autoreceptor signalling remains intact. That is the strongest conceptual reason the compound continues to attract research interest.
The honest qualification is that the comparison rests largely on descriptive differences in older experiments rather than on head-to-head modern studies with matched exposure, matched timing and shared endpoints. The indexed English-language literature does not contain a developed abuse-liability characterisation using current standards, such as conditioned place preference and operant reinforcement models evaluated against reference stimulants, so claims that the compound carries a different reinforcement profile are inferences from behavioural descriptions rather than conclusions from dedicated studies. A laboratory treating bromantane as mechanistically novel should treat that novelty as the hypothesis under test, not as the premise of the experiment.
Can the models and endpoints be compared in a single index?
Yes, and setting the evidence out by model type is the fastest way to see where the record is dense and where it is empty. The table below indexes the model categories that appear in the bromantane literature, the endpoints they generate, the direction of what is reported, and the limits that apply. The accessible English-language synthesis for the class and for bromantane within it is the 2012 actoprotector review (PMID 24009833); most of the underlying primary reports are Russian-language papers from the 1990s and 2000s with brief indexed abstracts.
| Model system | Typical endpoints | What the literature reports | Principal limits |
|---|---|---|---|
| Cell-free and biochemical assays | Enzyme activity, binding panels | Very little published bromantane-specific work | Sparse record, low aqueous solubility |
| Cultured cells | Viability, transcript and protein expression | Limited; most expression data are not cell-based | Vehicle and cytotoxicity controls often unreported |
| Ex vivo brain tissue from treated rodents | Tyrosine hydroxylase and AADC expression, regional monoamine content | Increased synthesis enzyme expression in hypothalamic and midbrain tissue | Cannot separate direct from indirect action |
| In vivo microdialysis | Extracellular dopamine and metabolites | Slower, sustained striatal dopamine increase versus releasers | Probe and strain variables, no independent replication |
| Rodent behaviour | Open field, plus maze, forced swim, avoidance | Mild activation without stereotypy, anxiolytic-like profile | Blinding, group size and locomotor covariates underreported |
| Work capacity and stress tolerance | Weighted swim, treadmill, hypoxia, heat | Preserved performance under adverse conditions | Confounded by thermoregulation, mass and motivation |
| Immune and inflammatory | Cell counts, antibody response, phagocytosis | Normalisation of stress-suppressed parameters | Weakest tier, dated assays, minimal detail |
| ADME and analytical chemistry | Tissue distribution, metabolite identification, detection windows | High lipophilicity, brain penetration, long urinary detection | No modern integrated pharmacokinetic study indexed in English |
Read across the table, the pattern is clear: the whole-animal rows are populated and the cell-based rows are not. That asymmetry, rather than any single finding, is the defining feature of the bromantane evidence base in 2026.
What are the main limitations of the bromantane evidence base?
Five limitations deserve to be stated together, because each one is routinely omitted when this literature is summarised elsewhere. The first is access. A large fraction of the primary work is in Russian, often in journals with short indexed abstracts and no accessible full text, so most English-language summaries are summarising summaries. Claims propagate through citation chains without anyone re-reading the source.
The second is era and method. The bulk of the work predates current expectations for randomisation, blinded outcome scoring, pre-specified analysis, sample size justification and data availability. That does not make the findings wrong, but it means effect sizes cannot be trusted at face value and publication bias cannot be estimated.
The third is concentration within a single research tradition. Independent replication by unrelated groups is what converts a reported effect into a known effect, and for bromantane that independent layer is largely missing from the open literature.
The fourth is the in vitro gap described throughout this page. Without clean cell-based work defining direct targets, potency and selectivity, the mechanistic account remains a plausible narrative assembled from whole-animal observations.
The fifth is the translational boundary. Every study described here was conducted in rodents or in tissue, and none of it supports a statement about effects, safety or utility in humans. Bromantane is a prohibited substance in sport, it is not an approved product in the United States, and it is handled in the laboratory setting as a research chemical. Research findings in animals describe the model, not people.
This page is general information, not legal advice; consult a qualified attorney for advice on any specific situation.
What would a modern laboratory program on bromantane need to establish?
The open questions are specific enough to list. A modern program would start with physicochemical characterisation under the assay conditions actually used, because solubility and stability determine whether a nominal concentration in a well is the real exposure. It would then run a target-deorphaning layer: transporter uptake and binding assays, broad receptor and enzyme panels, and counterscreens, to establish whether bromantane has any direct high-affinity interaction at all or whether its activity is entirely downstream and expression-mediated.
If the expression hypothesis survives, the next layer is a cell model expressing the catecholamine synthesis machinery, with transcript, protein and functional enzyme activity measured in the same experiment across a concentration ladder bracketed by viability testing, plus vehicle arms matched to the carrier and a reference compound with a known effect on the pathway. A time course matters here more than usual, because a transcriptional mechanism should show a characteristic delay that a transporter mechanism would not.
In whole animals, the useful modern contribution would be a pharmacokinetic and pharmacodynamic study linking plasma and brain concentrations to the neurochemical endpoint in the same animals, with both sexes and more than one strain, blinded behavioural scoring, automated tracking, and locomotor activity reported as a covariate for anxiety-like and despair-type measures.
Real Peptides does not provide preparation, handling or use guidance for any catalog compound, because these materials are supplied for laboratory research only and study parameters belong to the investigator and the institution's own review process.
How do researchers verify bromantane identity before preclinical work?
Identity verification comes before experimental design, because a mislabelled or poorly characterised material invalidates every downstream result and wastes the animals or cells committed to it. The baseline checks are the chemical name, N-(2-adamantyl)-N-(4-bromophenyl)amine, the molecular formula C16H20BrN, the molar mass near 306 g/mol and the CAS number commonly listed as 87913-26-6, each confirmed against the documentation supplied with the specific lot rather than against a general reference page. A research chemical with an adamantane core and a halogenated ring has recognisable analytical signatures, and the lot documentation should be consistent with them.
The second check is independent analysis. Real Peptides supplies research-use-only compounds and publishes independent third-party certificates of analysis for every batch, which can be reviewed at /coas/ before a purchase decision is made and matched to the lot identifier on the material received. Reading the certificate against the stated identity of the compound, rather than taking a product title at face value, is the single most useful procurement habit for a laboratory working with small molecules outside the mainstream catalog chemistry.
The catalog listing for this compound is at /products/bromantane/, the wider research catalog is at /shop/, and shipping and location details are published at /location/. Documentation, identity confirmation and lot traceability are the appropriate basis for selecting a research supplier; nothing on this page, and nothing in the preclinical literature it summarises, describes a use in humans.
For researchers building a mechanism or safety page that links back to primary evidence, the structured index above is intended to be the citable asset: model category, endpoint, reported direction and limitation, with the accessible English-language synthesis identified and the boundaries of the record stated rather than hidden.
All compounds discussed on this page are sold for laboratory research use only and are not for human consumption.
References
- The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance. Biomolecules and Therapeutics. 2012. PMID: 24009833. pubmed.ncbi.nlm.nih.gov/24009833
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA